Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996;381(6584):661–6.

Article  CAS  PubMed  Google Scholar 

Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4 + cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996;381(6584):667.

Article  CAS  PubMed  Google Scholar 

Zaitseva M, Blauvelt A, Lee S, Lapham CK, Kiaus-Kovrun V, Mostowski H, et al. Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nat Med. 1997;3:1369–75.

Article  CAS  PubMed  Google Scholar 

Carrington M, Kissner T, Gerrard B, Ivanov S, O’Brien SJ, Dean M. Novel alleles of the chemokine-receptor gene CCR5. Am J Hum Genet. 1997;61(6):1261–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

An P, Martin MP, Nelson GW, Carrington M, Smith MW, Gong K, et al. Influence of CCR5 promoter haplotypes on AIDS progression in African–Americans. Aids. 2000;14(14):2117–22.

Article  CAS  PubMed  Google Scholar 

Claireaux M, Robinot R, Kervevan J, Patgaonkar M, Staropoli I, Brelot A, et al. Low CCR5 expression protects HIV-specific CD4 + T cells of elite controllers from viral entry. Nat Commun. 2022;13(1):521.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ansari-Lari MA, Liu X-M, Metzker ML, Rut AR, Gibbs RA. The extent of genetic variation in the CCR5 gene. Nat Genet. 1997;16(3):221–2.

Article  CAS  PubMed  Google Scholar 

Ometto L, Bertorelle R, Mainardi M, Giurisato M, Chieco-Bianchi L, De Rossi A. Analysis of the CC chemokine receptor 5 m303 mutation in infants born to HIV-1-seropositive mothers. Aids. 1999;13(7):871.

Article  CAS  PubMed  Google Scholar 

Quillent C, Oberlin E, Braun J, Rousset D, Gonzalez-Canali G, Métais P, et al. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. The Lancet. 1998;351(9095):14–8.

Article  CAS  Google Scholar 

Hutter G, Nowak D, Mossner M, Ganepola S, Allers K, Schneider T, et al. editors. Treatment of HIV-1 infection by allogeneic CCR5-D32/D32 stem cell transplantation: a promising approach [abstract# 719]. 15th Conference on Retroviruses and Opportunistic Infections; 2008.

Maeda K, Das D, Nakata H, Mitsuya H. CCR5 inhibitors: emergence, success, and challenges. Expert Opin Emerg Drugs. 2012;17(2):135–45.

Article  CAS  PubMed  Google Scholar 

Tan Q, Zhu Y, Li J, Chen Z, Han GW, Kufareva I, et al. Structure of the CCR5 chemokine receptor–HIV entry inhibitor maraviroc complex. Science. 2013;341(6152):1387–90.

Article  CAS  PubMed  Google Scholar 

Kayongo A, Gonzalo-Gil E, Gümüşgöz E, Niwaha AJ, Semitala F, Kalyesubula R, et al. Brief report: identification of elite and viremic controllers from a large urban HIV ambulatory center in Kampala, Uganda. J Acquir Immune Defic Syndr. 2018;79(3):394.

Article  PubMed  PubMed Central  Google Scholar 

Laeyendecker O, Redd AD, Lutalo T, Gray RH, Wawer M, Ssempijja V, et al. Frequency of long-term nonprogressors in HIV-1 seroconverters from Rakai Uganda. J Acquir Immune Defic Syndr. 2009;52(3):316.

Article  PubMed  PubMed Central  Google Scholar 

Walker WE, Kurscheid S, Joshi S, Lopez CA, Goh G, Choi M, et al. Increased levels of macrophage inflammatory proteins result in resistance to R5-tropic HIV-1 in a subset of elite controllers. J Virol. 2015;89(10):5502–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Walker BD, Yu XG. Unravelling the mechanisms of durable control of HIV-1. Nat Rev Immunol. 2013;13(7):487–98.

Article  CAS  PubMed  Google Scholar 

Sáez-Cirión A, Lacabaratz C, Lambotte O, Versmisse P. HIV controllers exhibit potent CD8 T cell capacity to 3 suppress HIV infection ex vivo and peculiar CTL 4 activation phenotype.

Lissina A, Chakrabarti LA, Takiguchi M, Appay V. TCR clonotypes: molecular determinants of T-cell efficacy against HIV. Curr Opin Virol. 2016;16:77–85.

Article  CAS  PubMed  Google Scholar 

Pereyra F, Jia X, McLaren P, Telenti A, de Bakker P, Walker B. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (80-)[Internet]. 2010 Dec 10; 330 (6010): 1551–7.

Ferre AL, Hunt PW, McConnell DH, Morris MM, Garcia JC, Pollard RB, et al. HIV controllers with HLA-DRB1* 13 and HLA-DQB1* 06 alleles have strong, polyfunctional mucosal CD4 + T-cell responses. J Virol. 2010;84(21):11020–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amanya SB. VARIATIONS IN TRIM5α AND CYCLOPHILIN A GENES AMONG HIV-1 ELITE CONTROLLERS AND NON CONTROLLERS IN UGANDA. Makerere University; 2019.

Ganser-Pornillos BK, Pornillos O. Restriction of HIV-1 and other retroviruses by TRIM5. Nat Rev Microbiol. 2019;17(9):546–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Javanbakht H, An P, Gold B, Petersen DC, O’Huigin C, Nelson GW, et al. Effects of human TRIM5α polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology. 2006;354(1):15–27.

Article  CAS  PubMed  Google Scholar 

Gonzalo-Gil E, Rapuano PB, Ikediobi U, Leibowitz R, Mehta S, Coskun AK, et al. Transcriptional down-regulation of ccr5 in a subset of HIV + controllers and their family members. Elife. 2019;8:e44360.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salem A-H, Batzer MA. Distribution of the HIV resistance CCR5-∆32 allele among Egyptians and Syrians. Mutat Research/Fundamental Mol Mech Mutagen. 2007;616(1–2):175–80.

Article  CAS  Google Scholar 

Barmania F, Potgieter M, Pepper MS. Mutations in CC chemokine receptor type 5 (CCR5) in south african individuals. Int J Infect Dis. 2013;17(12):e1148–e53.

Article  CAS  PubMed  Google Scholar 

McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. The Lancet. 1998;352(9131):866.

Article  CAS  Google Scholar 

Mummidi S, Ahuja SS, Gonalez E, Anderson SA, Santiago EN, Stephan KT, et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med. 1998;4:786–93.

Article  CAS  PubMed  Google Scholar 

Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, Combadiere C, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med. 1997;3(1):23–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mehlotra RK. CCR5 promoter polymorphism – 2459G > A: forgotten or ignored? Cells. 2019;8(7):651.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kostrikis LG, Neumann AU, Thomson B, Korber BT, McHardy P, Karanicolas R, et al. A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to african-american infants. J Virol. 1999;73(12):10264–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

John GC, Bird T, Overbaugh J, Nduati R, Mbori-Ngacha D, Rostron T, et al. CCR5 promoter polymorphisms in a kenyan perinatal human immunodeficiency virus type 1 cohort: association with increased 2-year maternal mortality. J Infect Dis. 2001;184(1):89–92.

Article  CAS  PubMed  Google Scholar 

Singh KK, Hughes MD, Chen J, Phiri K, Rousseau C, Kuhn L, et al. Associations of chemokine receptor polymorphisms with HIV-1 mother-to-child transmission in sub-saharan Africa: possible modulation of genetic effects by antiretrovirals. J Acquir Immune Defic Syndr. 2008;49(3):259.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gabagaya G, Rukundo G, Amone A, Wavamunno P, Namale-Matovu J, Lubega I, et al. Prevalence of undetectable and suppressed viral load in HIV-infected pregnant women initiating option B + in Uganda: an observational study nested within a randomized controlled trial. BMC Infect Dis. 2021;21(1):1–7.

Article  Google Scholar 

Price H, Lacap P, Tuff J, Wachihi C, Kimani J, Ball TB, et al. A Trim5alpha exon 2 polymorphism is associated with protection from HIV-1 infection in Pumwani sexworker cohort. AIDS. 2010;24(12):1813.

Article  CAS  PubMed  Google Scholar 

Chakrabarti LA, Simon V. Immune mechanisms of HIV control. Curr Opin Immunol. 2010;22(4):488–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008;197(4):563–71.

Article  PubMed  Google Scholar 

Meijerink H, Indrati AR, van Crevel R, Joosten I, Koenen H, van der Ven AJ. The number of CCR5 expressing CD4 + T lymphocytes is lower in HIV-infected long-term non-progressors with viral control compared to normal progressors: a cross-sectional study. BMC Infect Dis. 2014;14(1):1–9.

Article